Strategic Financing Trellis Bioscience recently closed a $9 million Series C financing and has ongoing funding of $35 million total, signaling fundraising momentum and potential for collaboration or co-development partnerships with investors and strategic buyers seeking early access to innovative infectious disease therapies.

Board Expansion Appointment of Junjun Gao to the Board alongside AMRAF’s investment indicates strengthened governance and industry expertise, creating openings for executive-level introductions and advisory-backed outreach to potential pharma partners and licensing opportunities.

Leading Asset TRL1068 targets a highly conserved DNABII epitope across Gram-positive and Gram-negative bacteria with high-affinity binding and a favorable safety profile implied by Fast Track and QIDP designations, presenting a compelling collaboration or out-licensing candidate for infectious disease and biofilm-related product development.

Clinical-stage Focus As a clinical-stage biotech with a native human mAb platform and proprietary CellSpot technology, Trellis offers potential for co-development deals, milestone-driven partnerships, and potential out-licensing of core platforms to larger biopharma seeking rapid expansion in antimicrobial oncology or infectious disease pipelines.

Market Position With a revenue range of tens of millions and a lean team, Trellis presents as an attractive partner for large pharma seeking innovative early-stage assets, potential strategic alliances to accelerate development timelines, and opportunities to integrate with broader antimicrobial resistance (AMR) portfolios.